Rack of empty laboratory sample tubes with blue caps on a pale blue bench, illustrating the rules for marketing genetic and DNA tests in Singapore.
Home » Blog » Marketing Genetic Tests and DNA Kits in Singapore: MOH, HSA and Lab-Test Advertising Rules

Marketing Genetic Tests and DNA Kits in Singapore: MOH, HSA and Lab-Test Advertising Rules

Selling a DNA, ancestry or wellness gene test in Singapore? The clinical vs non-clinical line, MOH's banned claims and disclaimer, HSA's lab-test ad ban and insurance rules.

Last updated 16 November 2026 — by Adrian Tan, SDM. Marketing guidance, not legal or medical advice. References are to MOH guidance and circulars, HSA guidelines and legislation on Singapore Statutes Online as read on 16 November 2026. Where we interpret how a rule applies, we say so.

Genetic testing has become a consumer product. Ancestry kits are sold as Christmas gifts, “DNA diet” plans promise meals matched to your genes, fitness apps offer gene-based training, and health-screening packages bundle lab tests with a doctor’s review. In Singapore, these products are marketed on Instagram, through influencers and on e-commerce platforms alongside skincare and supplements.

The rules that govern that marketing are unusual. Most of the products are not regulated by any statute at all, yet MOH has published unusually specific copywriting guidance: example claims you should not make, mandated disclaimer wording and an annex of conditions a consumer test should not mention. The moment a test crosses into clinical territory, it falls into a licensed regime where it cannot be sold directly to consumers. And a 2025 HSA guideline bans public advertising of a whole class of lab tests outright.

This guide is for DTC genetic-testing companies, wellness and nutrition brands that sell gene-based products, labs and health-screening providers, and the agencies that run their campaigns. Our general guides to healthcare marketing in Singapore and health product advertising cover the broader regime; here we focus on what is specific to genetic and lab tests.

The short version

  • The clinical line decides everything. A test used for diagnosis, carrier status, predictive or disease-risk testing, or drug response is clinical, and clinical genetic tests cannot be offered directly to consumers in Singapore.
  • Wellness, ancestry, fitness and nutrigenomics tests can be sold directly, but MOH’s guidance says they should be marketed as recreational or non-clinical, with no medical information or advice, implied or otherwise.
  • Disclaimers do not rescue a clinical test. A test that does the same job as a clinical test is clinical “regardless of any disclaimers used”.
  • Labs can only test on a requestor’s order. A clinical laboratory may not test a Singapore resident unless a doctor or other requestor orders it.
  • Laboratory-developed tests must not be advertised to the public, under HSA’s September 2025 guideline.
  • Insurance and privacy claims need care. Insurers are bound by a moratorium, and a Genetic Information Bill is expected in 2027.

Clinical or non-clinical: the line that decides what you can sell

MOH’s Guidance for the Provision of Non-Clinical Genetic Testing (May 2021) is the starting point. It defines a direct-to-consumer genetic test as one that is not ordered by a medical practitioner, and it sorts tests into two groups.

A test is clinical if it is used for diagnosis, carrier testing, predictive or presymptomatic testing, pharmacogenetics (how a person responds to drugs) or disease-risk prediction. It is also clinical if the report uses terms that “connote meanings similar to medical conditions or induce consumers to seek further medical solutions”. The guidance lists genes whose testing makes a test clinical, including BRCA1 and BRCA2 (hereditary breast and ovarian cancer), LDLR, APOB and PCSK9 (familial hypercholesterolaemia), HBA1, HBA2 and HBB (thalassaemia) and MSH2 (Lynch syndrome). And it says a test that performs the same function as a clinical test is clinical “regardless of any disclaimers used”.

A test is non-clinical if it is for ancestry, talent, fitness, wellness or nutrigenomics, and it is marketed as recreational or for non-clinical purposes.

The consequence is stark. Paragraph 4.1 of the guidance states that “clinical genetic tests cannot be offered as DTC tests in Singapore”. MOH’s Code of Practice on genetic testing (circulated in December 2020) says the same: clinical genetic testing, laboratory genetic testing and genetic counselling “shall not be offered or provided by manufacturers or suppliers of genetic tests directly to consumers … in any circumstances, whether or not for a fee.”

Which side of the line is your test on?MOH Guidance for the Provision of Non-Clinical Genetic Testing (May 2021), paras 2-5Non-clinical: DTC allowedAncestry, talent, fitness,wellness, nutrigenomicsMarketed as recreationalNo medical info or advice,implied or otherwiseMOH disclaimer on page,ads, consent and reportClinical: no DTCDiagnosis, carrier, predictive,disease risk, drug responsee.g. BRCA1/2, LDLR, APOB,PCSK9, HBB, MSH2Doctor-ordered, licensed lab,counselling offeredA test that does a clinical test’s job is clinical “regardless of any disclaimers used”.
The line is set by what the test does and how the report reads, not by what the label says. Source: MOH non-clinical genetic testing guidance (May 2021).

Is the non-clinical guidance binding?

Not as such. MOH has said it does not regulate DTC wellness, ancestry or nutrigenomics tests and takes a risk-based approach, and the 2021 document is framed as guidance. But two things give it teeth in practice. First, a product that drifts into clinical claims stops being a wellness test and becomes a clinical laboratory or genetic testing service, which is licensed under the Healthcare Services Act. Second, HCSA section 31A prohibits anyone who is not a licensee from advertising a skill or service relating to the treatment of an ailment or condition, with penalties of up to $20,000 and 12 months’ jail, plus $1,000 a day for a continuing offence. In our reading, a “wellness” kit whose ads promise to manage a medical condition is the kind of marketing that brings both into play.

What a non-clinical test may and may not claim

The guidance is unusually concrete about marketing. It applies to adverts, marketing materials, reports and follow-up services, including add-ons such as e-consultations with dieticians.

No medical information, implied or otherwise

Paragraph 5.1 says these materials must not carry medical information or advice, “implied or otherwise”. It gives examples of statements that should not be made, such as claiming a test can “help you to prevent diseases such as type 2 diabetes”. Annex A lists conditions a non-clinical test should not report on, including obesity, hypertension, cancers, infertility and depression.

The mandated disclaimer

The guidance sets out disclaimer wording to appear on the pre-purchase page, marketing materials, the consent form and the report. It begins: “the test cannot be used to assess the risk of disease or conditions”. In our reading, that means the disclaimer belongs in the ad or landing page itself, not only in the terms and conditions.

No overstated accuracy or effect

Paragraph 5.2 flags claims such as “99.5% accurate” sequencing and promises to “reverse the effect of your genes” as misleading. Providers should disclose sensitivity, specificity and predictive value, and the populations those figures were derived from. Where results lead to “personalised” supplements, the guidance asks for a cautionary note. Our health product advertising guide covers the separate rules on supplement claims.

Draft claim Problem Safer approach
“Find out your risk of breast cancer” Disease-risk prediction: a clinical test; cancers are in Annex A Not offerable as DTC. Refer to clinical genetic testing via a doctor
“Discover the diet that prevents diabetes” Medical claim; MOH’s own example of what not to say “Explore how your genes relate to taste and nutrition preferences, for fun”
“99.9% accurate DNA results” Overstated accuracy without context State tested markers, method and limitations
“Reverse your genetic destiny” MOH flags “reverse the effect of your genes” Drop it
“Gene-matched weight-loss plan” Obesity is in Annex A; implies medical outcome Frame as general wellness without weight-loss promises
“Know which medicines work for you” Pharmacogenetics: a clinical test Not offerable as DTC

Privacy commitments in the marketing

Paragraph 5.3 asks providers to obtain PDPA-compliant consent, disclose any secondary use of data and how samples are stored, explain what happens to data if the company closes, and check the Do Not Call registers before marketing by phone or SMS. Our guide to PDPA compliance in marketing covers consent and DNC checks in detail. The maximum financial penalty under the PDPA is 10% of Singapore turnover where that exceeds $10 million, and $1 million otherwise.

Clinical tests, labs and health screening

Once a test is clinical, the question for a marketer changes from “what may we claim” to “who may we sell to”. Three rules shape it.

A lab may only test on a requestor’s order

The HCSA defines a clinical laboratory service to include testing for “assessing the health or genetic predisposition” of an individual, and genetic labs must be licensed under the molecular pathology discipline. Regulation 13 of the Clinical Laboratory Service and Radiological Service Regulations 2021 then says a licensee must not test a patient who resides in Singapore unless a “requestor” orders the test. A requestor is a doctor, a dentist, a collaborative prescribing practitioner or a person approved by the Director-General. MOH’s FAQs add that screening tests need a doctor’s order, and that mass screening exercises need clinical oversight, including follow-up of abnormal results.

For marketing, this means a lab cannot run a “walk-in, no doctor needed” campaign for clinical tests. A health-screening package can be sold to the public by a licensed provider, but the doctor’s order and review are part of the service, and the ads should not imply otherwise. Providing a licensable service without a licence carries a fine of up to $100,000, up to two years’ jail or both under HCSA section 8.

The incoming clinical genetic testing tiers

MOH Circular 11/2025 (14 March 2025) sets out a tiered framework for clinical genetic testing: Levels 1, 2A, 2B/2C and 3. Every test is Level 3 unless it has been whitelisted, and pre-test and post-test counselling must be offered. Outpatient clinics offering Level 3 tests will need MOH approval as a Specified Service before starting. The circular’s Annex E lists 18 pre-test counselling items, including the impact on insurability and employment. Enforcement is tied to a sunrise period that, as of November 2026, we could not find announced, so check the current position before relying on any date.

HSA: laboratory-developed tests must not be advertised

The rule most likely to catch a lab’s marketing team is in HSA’s revised guideline GL-08-R2 on laboratory-developed tests (September 2025). Section 3.3.1 says: “LDTs must not be advertised to the general public.” Advertising is permitted only in publications for qualified practitioners, and must not be false or misleading. A kit distributed outside the lab that developed it is regulated as a commercial in vitro diagnostic device instead. MOH relayed the revised guideline to clinical laboratory licensees in a March 2026 circular.

In practice, a lab that has developed its own genetic panel can promote it to doctors through professional channels, but not through Instagram ads, influencer posts or consumer search campaigns. HSA’s medical-device advertising guidance separately bans public advertising of “professional use only” devices.

Who may see the ad?MOH guidance and Code of Practice; CLS Regulations reg 13; HSA GL-08-R2 (Sep 2025)Non-clinical DTC kitPublic, as recreational, with MOH disclaimerLicensed screening / clinical testPublic may learn of it; a requestor must order the testLaboratory-developed testQualified practitioners only, no public adsClinical genetic test (supplier)Never direct to consumersThe audience a campaign can target depends on the test category before any copy is written.
Targeting is decided by test category. Sources: MOH; Clinical Laboratory Service and Radiological Service Regulations 2021; HSA GL-08-R2.

The general healthcare advertising rules still apply

The Healthcare Services (Advertisement) Regulations 2021 contain no provisions specific to labs or screening, but the generic rules apply to every licensee’s ads: no superlatives, comparisons, unjustified expectations or testimonials (regulation 5), no push advertising such as SMS or email without the recipient’s consent (regulation 6(4)), and no gift-with-purchase programmes (regulation 15). Our guides to telemedicine advertising and fertility clinic advertising show how these rules apply to other licensed services.

Insurance, privacy and the Genetic Information Bill

Many consumers hesitate to test because they fear the results will affect their insurance. Marketers often want to address that fear, and the rules here are specific enough to state accurately.

The MOH and Life Insurance Association Moratorium on Genetic Testing and Insurance dates from October 2021 and was amended for policies from 30 June 2025. Under it, insurers cannot require applicants to take a genetic test, and may use predictive results only for Huntington disease and BRCA1/2 tests, and only above set financial limits, such as a $2 million sum assured for life cover. In a May 2023 reply, MOH said insurers are not allowed to request the disclosure of DTC, non-clinical and predictive genetic test results.

The legal position is due to tighten. MOH consulted on a proposed Bill to protect genetic information from 7 August to 4 September 2026, and expects to table it in Parliament in 2027. As proposed, it would cover insurers and employers, extend to results derived from commercially available genetic tests, and keep an exception for large policies. The consultation paper cites a survey finding that two in five Singaporeans have concerns about genetic testing.

For marketing copy, that supports factual statements such as “Under the current industry moratorium, insurers may not ask you to disclose the results of this test”. It does not support “your results can never affect your insurance”, which overstates the position for clinical predictive tests above the financial limits. Our insurance advertising guide covers the insurers’ own rules.

Ad platforms

Google treats health as a sensitive interest category, so advertisers cannot use their own curated audiences, such as remarketing lists or Customer Match, to target people based on health. Google’s Singapore-specific healthcare certifications cover only over-the-counter medicine manufacturers and HCSA-licensed telemedicine, so there is no genetic-test certification to apply for. Meta’s personal-attributes policy bars ads that assert or imply knowledge of a person’s physical or mental health, including medical conditions; its banned example is “Do you have diabetes?”.

That last rule interacts neatly with MOH’s guidance: an ad that asks “Worried about your family history of heart disease?” fails Meta’s policy and drifts into clinical territory at the same time. Lead with the product (“Explore your ancestry and traits”) rather than the viewer’s health.

Market context worth knowing

Clinical genetic testing is becoming more accessible through public channels, which raises the bar for private marketing claims. From 1 December 2026, MOH will subsidise hereditary breast and ovarian cancer (HBOC) genetic testing by up to 70%, means-tested, at NCCS, NCIS and TTSH. MOH says an index test costing about $1,000 can fall to $0 after subsidy and MediSave, that about 1 in 150 Singaporeans carry an HBOC variant, and that about 2,000 people a year are expected to benefit. A national familial hypercholesterolaemia genetic testing programme launched in June 2025.

For a private provider, the implication is simple: BRCA and similar tests are clinical and belong in a doctor-led pathway, and consumers increasingly know that a subsidised route exists. A DTC wellness brand that hints at cancer risk is not only off-side with MOH’s guidance; it is competing against a cheaper, clinically supported option.

A worked example: a nutrigenomics brand’s launch campaign

A Singapore start-up sells a cheek-swab kit with a report on caffeine metabolism, lactose tolerance and taste preferences, bundled with an optional dietitian e-consult and personalised supplement recommendations. Its draft campaign reads: “Your DNA holds the key to preventing diabetes and losing weight. 99.9% accurate. Insurers will never see your results.”

  • “Preventing diabetes”: MOH’s own example of a claim not to make, and a condition-related claim. Remove.
  • “Losing weight”: obesity is in Annex A. Reframe as general nutrition preferences.
  • “99.9% accurate”: replace with what was tested, the method and its limitations, with sensitivity and specificity where available.
  • “Insurers will never see your results”: overstated. Replace with an accurate statement of the moratorium.
  • Dietitian e-consult and supplements: the guidance covers follow-up services too, so the dietitian’s scripts need the same no-medical-advice discipline, and supplement recommendations need a cautionary note.
  • Disclaimer and privacy: add MOH’s disclaimer to the landing page, consent form and report; disclose sample storage and secondary use; check the DNC registers before any SMS follow-up.
  • Targeting: broad interest targeting around food and fitness, with no health-condition audiences on Google or Meta.

The rewritten campaign, “Discover how your genes relate to coffee, dairy and taste, for curiosity, not diagnosis”, is less dramatic but publishable, and it avoids the problem of a consumer reading a recreational report as medical advice.

A pre-launch checklist

  1. Classify the test: clinical or non-clinical, using MOH’s definitions and gene list, before writing any copy.
  2. If clinical: no direct-to-consumer offer; licensed lab; requestor order; counselling offered.
  3. If laboratory-developed: no public advertising; professional channels only.
  4. If non-clinical: no medical information or Annex A conditions; MOH disclaimer on every customer-facing material.
  5. Claims: no unqualified accuracy figures; no “reverse your genes”.
  6. Privacy: PDPA consent, storage and secondary-use disclosures; DNC checks.
  7. Insurance statements: describe the moratorium accurately; do not promise more.
  8. Platforms: no health-condition targeting or copy that implies the viewer’s health.

The bottom line

Genetic testing marketing in Singapore turns on classification. Wellness, ancestry and nutrition tests can be sold directly, provided the marketing stays recreational, carries MOH’s disclaimer and avoids anything that reads as medical advice. Clinical tests belong in a doctor-ordered, licensed pathway and cannot be offered directly to consumers. Lab-developed tests cannot be advertised to the public at all. Get the classification right first, and most of the copy decisions follow from it.

If you market tests, screening or health products and want campaigns built inside these rules from the first brief, our performance marketing team works with healthcare and wellness brands, and our performance marketing guide explains how we plan and measure campaigns. You can see examples of our work in our case studies.

Frequently asked questions

Can I sell a DNA test directly to consumers in Singapore?

Yes, if it is a non-clinical test such as ancestry, fitness, wellness or nutrigenomics, marketed as recreational. Clinical genetic tests, used for diagnosis, carrier status, predictive or disease-risk testing or drug response, cannot be offered directly to consumers and must be ordered by a doctor.

Does a disclaimer make a health-related gene test non-clinical?

No. MOH’s guidance says a test that performs the same function as a clinical test is clinical regardless of any disclaimers used. Non-clinical tests must still carry MOH’s disclaimer, but it cannot convert a clinical test.

Can a lab advertise its own in-house genetic panel to the public?

No. HSA’s 2025 guideline on laboratory-developed tests says they must not be advertised to the general public. They can be promoted only in publications for qualified practitioners, and the advertising must not be false or misleading.

Can a lab run a test without a doctor’s referral?

Not for a Singapore resident. Regulation 13 of the Clinical Laboratory Service and Radiological Service Regulations 2021 says a licensed lab must not test a patient unless a requestor, usually a doctor, orders the test.

Can we tell customers their results will not affect their insurance?

Describe the moratorium accurately. Insurers cannot require testing and are not allowed to request DTC or non-clinical results, and may use predictive results only for Huntington disease and BRCA1/2 tests above set financial limits. A Genetic Information Bill is expected in 2027.

Can we target ads at people with a family history of a disease?

No. Google treats health as a sensitive category and does not allow curated health audiences, and Meta bars ads that imply knowledge of a person’s medical condition. Such targeting would also signal a clinical purpose that DTC tests cannot have.



Want to know where you actually rank?

We will run a free visibility check across your target searches and send back an honest read — no obligation.

Picture of Adrian Tan

Adrian Tan

A seasoned digital marketing professional with over 15 years of experience, I have built and executed high-impact digital strategies across SEO, SEM, Social Media Marketing (SMM), Social Media Advertising (SMA), content marketing, performance marketing, and integrated digital campaigns. My expertise extends beyond individual channels, focusing on how every aspect of digital marketing works together to drive measurable business growth. Throughout my career, I have successfully managed and optimized campaigns across a wide range of industries, including technology, finance, healthcare, retail, e-commerce, education, real estate, hospitality, and professional services. This cross-industry experience has enabled me to develop data-driven strategies tailored to unique business objectives, customer behaviors, and competitive landscapes. I have partnered with multinational corporations (MNCs) as well as established enterprises and high-growth businesses, helping them strengthen their digital presence, increase brand visibility, generate qualified leads, improve customer acquisition, and maximize return on marketing investment. From developing comprehensive digital strategies to managing multi-channel campaigns with substantial budgets, I have consistently delivered results through continuous optimization, analytics, and innovation. My expertise includes technical and on-page SEO, enterprise SEO strategies, paid search (Google Ads, Microsoft Ads), paid social campaigns across Meta, LinkedIn, TikTok, and other platforms, marketing automation, conversion rate optimization (CRO), web analytics, audience segmentation, content strategy, and performance reporting. I combine analytical thinking with creative problem-solving to ensure every campaign aligns with broader business goals. What sets me apart is my holistic understanding of the digital marketing ecosystem. Rather than viewing SEO, paid media, social media, and content as isolated disciplines, I develop integrated strategies where every channel supports the customer journey—from awareness and engagement to conversion, retention, and advocacy. This full-funnel approach allows businesses to achieve sustainable growth while adapting to evolving market trends and consumer expectations. Driven by continuous learning and innovation, I stay at the forefront of emerging technologies, AI-powered marketing, automation, and evolving digital platforms. My passion lies in transforming complex marketing challenges into scalable, measurable, and sustainable growth opportunities that deliver long-term business success.

On this page

Share

Get found by customers already looking for you

A free, honest look at where you stand today and what it would take to move.

Not sure where you stand?

Tell us about your business and we will take an honest look at where you are today — and what it would take to get where you want to be.

No obligation · a human replies within one working day